Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Vascular Risk Assessment Service VaRAS

Reference number
Coordinator ARTEC Diagnosis AB
Funding from Vinnova SEK 300 000
Project duration April 2019 - November 2019
Status Completed
Venture Innovative Startups
Call Innovative Startups step 1 spring 2019

Important results from the project

An aortic aneurysm is a local enlargement of the aorta. It is the most common aortic disease and their treatment represents a considerable health care challenge. Given clinical parameters, such as the aortic diameter, clinicians decide upon interventional treatment, so called aortic repair. Current treatment is sub-optimal and out of 10 patients only 1 would require aortic repair. A service platform platform with detailed information whether or not an individual patient requires aortic repair could successfully started to be developed by this project.

Expected long term effects

The outcome from this VINNOVA’s Innovative Startups project, together with the ongoing clinical validation studies is now the basis of VaRAS’ commercialization plan. The development of a convincing business strategy has been the main priority in this early development phase of our project. A business strategy plan could be developed and provides now a sound basis for the acquisition of sufficient funding, such that VaRAS will be able to enter a phase of sustainable business development. Last but not least VaRAS’ business feasibility could be verified within this project.

Approach and implementation

1. Explore VaRAS’ business feasibility and plan its market entry phase: a specification of the market strategy and goals for market entry could be set and a plan for a targeted market entry with cost estimates and exit strategies could be developed. 2. Establish further clinical contacts to reach the clinical community: communication platforms of vascular clinicians could be explored and a plan to communicate VaRAS’ value at clinical meetings could be defined to continuously update the vascular community. An assessment summary regarding the value of sponsoring could be developed.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 24 January 2020

Reference number 2019-00460